Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Single Site Pacing, Dual Site Pacing · 1 trial · 4 indications
Left ventricular end diastolic volume (LVEDV) was measured by echocardiogram. Change was measured as Month 18 LVEDV minus baseline LVEDV. Per protocol, change in LVEDV is compared between Pooled Pacing (Single site + Dual Site) and Control.
| Arm | Type | Description |
|---|---|---|
| Single Site Pacing | EXPERIMENTAL | - |
| Dual Site Pacing | EXPERIMENTAL | - |
| Control | NO_INTERVENTION | - |
| Name | Type | Description |
|---|---|---|
| Single Site Pacing | DEVICE | Subjects will be implanted with a CRT-D that delivers pacing via the Left Ventricular lead. |
| Dual Site Pacing | DEVICE | Subjects will be implanted with a CRT-D that delivers pacing via the Left Ventricular and Right Ventricular lead. |
Inclusion Criteria: * Myocardial Infarction (MI) within the past 10 days * Peak Creatine Phosphokinase (CPK) greater than 3000 Units/Litre (U/L) at time of MI, or a troponin T (TnT) greater than 10 micrograms/Litre (mcg/L) * At least 18 years old * Willing to comply with the protocol Exclusion Cri...
Single Site Pacing, Dual Site Pacing is an investigational pacing therapy being studied for use in Acute Myocardial Infarction. It is intended to address cardiac remodeling and heart failure following a heart attack. The therapy is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
Single Site Pacing, Dual Site Pacing is being developed by Rhythm Pharmaceuticals, Inc., a company traded on the NASDAQ under the ticker symbol RYTM. The company is conducting clinical research to evaluate this pacing therapy for patients with Acute Myocardial Infarction.
Single Site Pacing, Dual Site Pacing is in Phase 2 clinical development. It is an investigational therapy, meaning it has not yet been approved for commercial use. The therapy is being studied for its potential to prevent cardiac remodeling and heart failure in patients who have experienced an Acute Myocardial Infarction.
Single Site Pacing, Dual Site Pacing has been studied in one completed clinical trial, identified as NCT01213251. This Phase 2 trial, titled 'Post-Myocardial Infarction Remodeling Prevention Therapy,' enrolled 129 participants across multiple countries including the United States, Denmark, France, Germany, Hungary, Saudi Arabia, and Slovakia.
Single Site Pacing, Dual Site Pacing is a specific investigational pacing approach being studied for Acute Myocardial Infarction. While it is related to pacing therapy concepts, it is distinct in its focus on preventing cardiac remodeling and heart failure after a heart attack. The therapy is still in clinical trials and not yet established as a standard treatment.